Investment Thesis
Eledon is a pre-revenue clinical-stage pharmaceutical company with $39M annual net losses and $22.6M quarterly operating cash burn against only $6.2M cash reserves, providing less than 3 months of operational runway. Despite a strong balance sheet structure ($146.7M assets, zero debt), the company exhibits deteriorating profitability (-32.3% YoY loss increase) and zero revenue generation, indicating significant execution risk without near-term approved products or financing catalysts evident in the data.
Strengths
- No debt burden with clean capital structure
- Strong current ratio of 8.44x indicating sufficient liquid assets for short-term obligations
- Substantial asset base of $146.7M providing development capital
Risks
- Zero revenue with no indication of approved or near-market products
- Unsustainable cash burn rate of $22.6M quarterly against only $6.2M cash reserves
- Net losses worsening year-over-year by 32.3% indicating accelerating cash consumption
- Critical liquidity crisis likely within 3 months without additional financing or revenue generation
- High execution risk typical of pre-clinical/early-stage pharmaceutical development
Key Metrics to Watch
- Cash position and monthly burn rate (critical for survival timeline)
- Clinical trial results and FDA approval status for pipeline candidates
- Operating cash flow and whether losses stabilize or accelerate
- Financing activities and dilutive capital raises
Financial Metrics
Revenue
0.0
Net Income
-39.0M
EPS (Diluted)
$-0.33
Free Cash Flow
-22.6M
Total Assets
146.7M
Cash
6.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-87.2%
ROA
-26.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.44x
Quick Ratio
8.44x
Debt/Equity
0.00x
Debt/Assets
31.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:12:43.219351 |
Data as of: 2026-03-31 |
Powered by Claude AI